UTHR · UNITED THERAPEUTICS Corp

$513.12 -7.88 (-1.51%) At close · Aug 21

Market Cap

$22.01B

42.89M

Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.

Revenue

$3.18B +10.6%

FY2025

Net Income

$1.33B +11.7%

FY2025

Gross Margin

87.92% -1.3pp

FY2025

Operating Margin

46.89% -1pp

FY2025

Diluted EPS

$27.86 +13.1%

FY2025

Operating Cash Flow

$1.56B +17.6%

FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics

Annual Quarterly

Line Item	3Y	5Y	10Y	TTM	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2009	FY2008
Revenue	+18.0%	+16.5%	+8.1%	$3.15B	$3.18B	$2.88B	$2.33B	$1.94B	$1.69B	$1.48B	$1.45B	$1.63B	$1.73B	$1.6B	$1.47B	$1.29B	$1.12B	$916.08M	$743.18M	$592.9M	$358.88M	$281.5M
Cost of Revenue	+36.4%	+28.9%	+18.7%	$437.2M	$384.4M	$309.7M	$257.5M	$151.6M	$122.5M	$108.1M	$117.6M	$198.7M	$105.7M	$72.7M	$69M	$125.9M	$131.13M	$119.3M	$88.9M	$67.67M	$40.86M	$26.96M
Gross Profit	+16.2%	+15.3%	—	$2.72B	$2.8B	$2.57B	$2.07B	$1.78B	$1.56B	$1.38B	$1.33B	—	—	—	—	$1.15B	$975.82M	$786.83M	$652.19M	$524.03M	$316.78M	—
Gross Margin	—	—	—	—	87.92%	89.24%	88.94%	92.17%	92.73%	92.71%	91.88%	—	—	—	—	89.53%	87.36%	85.89%	87.76%	88.38%	88.27%	—
Research & Development	+19.4%	+9.0%	+8.4%	$551.5M	$550M	$481M	$408M	$322.9M	$540.1M	$357.7M	$1.18B	$357.9M	$264.6M	$147.6M	$245.1M	$242.5M	$299.35M	$173.39M	$180.02M	$165.31M	$120.37M	$239.18M
Selling, General & Administrative	+16.2%	—	+5.3%	$764M	$755.8M	$709.7M	$477.1M	$482.1M	$467M	—	—	$265.8M	$330.1M	$316.8M	$452.7M	$381.3M	$394.01M	$201.75M	$156.48M	$188.61M	$171.89M	$94.31M
Amortization of Intangibles	+108.0%	+35.1%	-2.0%	—	$900K	$900K	$300K	$100K	$100K	$200K	$200K	$100K	$500K	$600K	$1.1M	$1.4M	$2.6M	$2.1M	$1.7M	$1.6M	—	—
Depreciation & Amortization	+18.6%	+11.4%	+10.0%	—	$85.6M	$72.5M	$53.2M	$51.3M	$49.9M	$49.9M	$45.9M	$35.9M	$31M	$31.6M	$32.9M	$32.2M	$31.26M	$27.15M	$20.54M	$17.92M	$11.39M	$4.54M
Total Costs & Expenses	+20.9%	+13.7%	+8.2%	$1.75B	$1.69B	$1.5B	$1.14B	$956.6M	$1.13B	$889.7M	$1.64B	$822.4M	$910.4M	$537.1M	$766.8M	$749.7M	$824.49M	$494.43M	$425.4M	$421.59M	$333.12M	$363.55M
Operating Income	+15.1%	+20.2%	+7.9%	$1.4B	$1.49B	$1.38B	$1.18B	$979.7M	$555.9M	$593.6M	-$187.6M	$805.4M	$814.9M	$1.06B	$699M	$538.8M	$292.5M	$421.65M	$317.78M	$171.31M	$25.76M	-$82.06M
Operating Margin	—	—	—	—	46.89%	47.86%	50.91%	50.6%	32.98%	40.02%	-12.95%	49.48%	47.23%	66.41%	47.69%	41.82%	26.19%	46.03%	42.76%	28.89%	7.18%	-29.15%
EBITDA	+15.2%	+19.7%	+8.0%	—	$1.58B	$1.45B	$1.24B	$1.03B	$605.8M	$643.5M	-$141.7M	$841.3M	$845.9M	$1.09B	$731.9M	$571M	$323.76M	$448.79M	$338.32M	$189.23M	$37.15M	-$77.52M
Interest Expense	-15.6%	-3.7%	+15.3%	$12M	$19.5M	$42.9M	$59.3M	$32.4M	$18.6M	$23.5M	$44.2M	$13.9M	$9M	$3.9M	$4.7M	$17.6M	$18.06M	$16.64M	$21.37M	$19.71M	$12.88M	$11.44M
Interest Income	+62.0%	+46.3%	—	$162.9M	$192M	$199.1M	$162.7M	$45.2M	$16.7M	$28.6M	$44.2M	$28.6M	$10.9M	$3.5M	—	—	$3.83M	$3.94M	$3.45M	$2.94M	$5.15M	$11.03M
Other Non-Operating Income	—	+37.3%	-4.3%	$171.2M	$221.4M	$162M	$89.4M	-$29.1M	$38M	$45.3M	$22.6M	-$46.5M	-$45.4M	-$1.5M	$345.4M	-$13.6M	-$13.6M	$19.03M	-$18.67M	-$16.16M	-$7.13M	-$1.67M
Equity in Earnings of Unconsolidated Entities	—	—	—	-$200K	—	—	—	—	—	—	—	—	—	—	—	—	—	-$143K	-$119K	-$160K	-$141K	-$226K
Investment Income (Loss)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-$7.69M	-$4.49M	-$1.6M
Pretax Income	+21.7%	+21.8%	+5.1%	$1.57B	$1.71B	$1.54B	$1.27B	$950.6M	$593.9M	$638.9M	-$165M	$758.9M	$769.5M	$1.06B	$1.04B	$525.2M	$278.9M	$440.67M	$299.12M	$155.15M	$18.62M	—
Income Tax	+19.3%	+25.0%	-0.4%	$262.1M	$379.2M	$343.9M	$289.5M	$223.3M	$118.1M	$124.1M	-$60.5M	$169.7M	$351.6M	$346.5M	$392.8M	$185.1M	$104.34M	$136.23M	$81.87M	$43.95M	-$695K	-$34.39M
Net Income	+22.4%	—	+7.4%	$1.31B	$1.33B	$1.2B	$984.8M	$727.3M	$475.8M	—	-$104.5M	$589.2M	$417.9M	$713.7M	$651.6M	—	—	—	—	$105.92M	$19.46M	-$49.33M
Net Margin	—	—	—	—	41.94%	41.53%	42.31%	37.56%	28.23%	—	-7.21%	36.2%	24.22%	44.64%	44.45%	—	—	—	—	17.86%	5.42%	-17.52%
Net Income Available to Common Stockholders	—	+11.7%	+9.1%	—	—	—	—	$727.3M	$475.8M	$514.8M	-$104.5M	$589.2M	$417.9M	$713.7M	$651.6M	$340.1M	$174.56M	$304.44M	$217.87M	$105.92M	$19.46M	—
Comprehensive Income	+24.4%	+21.1%	+7.5%	$1.29B	$1.34B	$1.2B	$1.03B	$694.8M	$467M	$514.8M	-$110.8M	$600.9M	$415.1M	$717.3M	$647.9M	$336.5M	$176.33M	$300.37M	$216.16M	$101.06M	$21.06M	—
EPS (Basic) USD/shares	+23.5%	+20.9%	+7.8%	—	$30.13	$26.44	$21.04	$15.98	$10.60	$11.65	-$2.39	$13.54	$9.50	$16.29	$14.17	$7.06	$3.49	$5.84	$3.81	$1.89	$0.37	-$1.08
EPS (Diluted) USD/shares	+22.9%	+19.3%	+8.2%	—	$27.86	$24.64	$19.81	$15.00	$10.06	$11.54	-$2.39	$13.39	$9.31	$15.25	$12.72	$6.28	$3.28	$5.71	$3.67	$1.78	$0.35	-$1.08
Shares Outstanding (Basic Avg) shares	-0.9%	0.0%	-0.4%	—	44.3M	45.2M	46.8M	45.5M	44.9M	44.2M	43.8M	43.5M	44M	43.8M	46M	48.2M	50.08M	52.09M	57.16M	56.14M	53.31M	45.8M
Shares Outstanding (Diluted Avg) shares	-0.4%	+1.4%	-0.7%	—	47.9M	48.5M	49.7M	48.5M	47.3M	44.6M	43.8M	44M	44.9M	46.8M	51.2M	54.2M	53.23M	53.28M	59.4M	59.52M	56.13M	45.8M

Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2011–FY2025: $4.07B in buybacks.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue

—

Peer median 3.51×

EV/EBIT

—

Peer median 19.77×

P/E (TTM)

18.38×

Peer median 23.97×

Peer medians compare against the 18 similar-size Drug Manufacturers - Specialty & Generic companies (of 104 listed).

Valuation over time computed as of each quarter's filing date

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Geography (USD)

Component	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
United States	$3,037,000,000	$2,739,700,000	$2,202,200,000	$1,814,100,000	$1,564,200,000	$1,412,100,000	$1,323,200,000	$1,528,200,000
Non Us	$145,700,000	$137,700,000	$125,300,000	$122,200,000	$121,300,000	$71,200,000	$125,600,000	—
European Union and Others	—	—	—	—	—	—	—	$99,600,000

By Product & Service (USD)

Component	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Tyvaso	$1,878,200,000	$1,620,400,000	$1,233,700,000	$873,000,000	$607,500,000	$483,300,000	$415,600,000	$415,200,000
TyvasoDPI	$1,292,500,000	$1,033,600,000	$731,100,000	$158,300,000	$0	—	—	—
Nebulized Tyvaso	$585,700,000	$586,800,000	$502,600,000	$714,700,000	$607,500,000	—	—	—
Remodulin	$526,800,000	$538,100,000	$494,800,000	$500,200,000	$513,700,000	$516,700,000	$587,000,000	$599,000,000
Orenitram	$496,900,000	$434,300,000	$359,400,000	$325,100,000	$306,100,000	$293,100,000	$225,300,000	$205,100,000
Unituxin	$226,800,000	$238,700,000	$198,900,000	$182,900,000	$202,300,000	$122,900,000	$113,700,000	$84,800,000
Adcirca	$30,000,000	$23,800,000	$28,900,000	$41,300,000	$55,900,000	$67,300,000	$107,200,000	$323,700,000
Product And Service Other	$24,000,000	$22,100,000	$11,800,000	$13,800,000	$0	$0	—	—

Key facts CIK 1082554 CUSIP 91307C102 13F (30d) 745 filings 721 filers Visit website Investor relations